-
Prof. Ludwig ist ein großartiger Wissenschaftler und Kollaborator. Seit Jahren arbeiten wir erfolgreich mit ihm zusammen, um
#ATR002 gegen#flu zu entwickeln.https://twitter.com/UK_Muenster/status/1222537013590745091 …
0:39 -
-
The world is under virus attack, but German scientists are already on the move.
@Tagesspiegel spoke with Prof. Dr. Ludwig, developer of@AtrivaTx’ host-targeting#antiviral candidate,#ATR002, about pandemic threats like#flu, SARS, MERS and#coronavirus. https://bit.ly/2O7CMrK pic.twitter.com/fT8OSsdVdv
-
We look forward to telling you more about
#ATR002, our host-targeting approach to treat#flu, at the RESI conference, where 500+ early stage investors gather every year. Dr. Rainer Lichtenberger will present Atriva during the track 4, 8:00 am.@LSciNation https://bit.ly/2N0MUlh pic.twitter.com/is4vr7crmV
-
Learn more about
@AtrivaTx’s host-targeting therapy candidate#ATR002 against#flu, hanta and further severe respiratory viral infections at the company presentation of our CEO, Dr. Lichtenberger, today at#BiotechShowcase. Join us at 11:30, Franciscan D. https://bit.ly/39PxxWE pic.twitter.com/4C0P2MzBMb
-
@rki_de reports the weekly status of Germany’s#flu incidence. As every year, the maximum is expected in February.@AtrivaTx’s is developing#ATR002 to reduce the occurrence of#flu and flu-like-illness by inhibiting the virus’ replication machinery independently of the strain.pic.twitter.com/4bdpkwZA7F
-
@AtrivaTx’s strategy and product candidate#ATR002 “may revolutionize treatment of#influenza and other severe respiratory viral infections” and be “a quantum leap in#antiviral respiratory therapies”. Learn more in the article by@bpdealmakers https://go.nature.com/2KDTqh0 pic.twitter.com/ATH2tiKcVY
-
@AtrivaTx announces the successful conclusion of the Ph. I trial for#MEKinhibitor#ATR002 in#influenza. Dr. Lichtenberger, CEO: “An important milestone towards a novel flu drug against this public health danger and its threat of a new#pandemic” https://bit.ly/2CoVwgb pic.twitter.com/mPl6i4n9yw
-
On Nov 11
#BIOEurope, EU's largest life science partnering conference, starts in#Hamburg. Our CEO Dr. Lichtenberger is happy to discuss our lead product#ATR002 against#influenza,#hanta and other severe respiratory infections. Use#partneringONE@EBDgroup to set up a meeting!pic.twitter.com/lDsTrTORhb
-
Let’s go
#viral by spreading awareness - today is#WorldInfluenzaDay! Atriva commits to#fightflu with our first-in-class host-targeting MEK inhibitor#ATR002. We address the need for a novel, broadly active, resistance-avoiding therapy and for a prolonged treatment window. pic.twitter.com/DxGvbFPfNV
-
Atriva Theraputics is now also on Twitter! We can’t wait to tell you more about our lead product
#ATR002, a clinical- stage, first-in-class host-targeting agent that inhibits viral replication in#influenza and other respiratory infections. Stay tuned!pic.twitter.com/pNCZdmmkDn
-
THIS ONES FOR ALL YOU DUBSTEP LOVERS
#ATR002 https://soundcloud.com/alltimeedm/alltime-radio-ep-002-feat-sicnick … -
Prikaži ovu nit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
Zum ausführlichen Interview: